Matches in SemOpenAlex for { <https://semopenalex.org/work/W2389274629> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2389274629 endingPage "1436" @default.
- W2389274629 startingPage "1431" @default.
- W2389274629 abstract "BACKGROUND & OBJECTIVE Capxol is a Cremophor-free,protein stabilized, nanoparticle formulation of paclitaxel. This phase I study was designed to evaluate the tolerability/safety, toxicity profile, and maximum tolerated dose (MTD) of Capxol administered intravenously in Chinese patients with advanced solid tumor, and to provide the recommending dose for the phase II trial. METHOD Capxol was administered intravenously over 30 minutes, no premedication was required. Doses of Capxol ranged from 135 to 350 mg/m(2). The treatment was repeated at 3 weeks interval. RESULTS 22 patients were treated with Capxol and totally 94 treatments cycles were completed. No acute hypersensitivity reactions were observed during the infusion period. The treatment was tolerated well. Most of AEs (95%) were grade 1/2; >/= grade 3 AEs were only 5%. The most common toxicities were mild leucopenia and peripheral sensory neuropathy. The dose-limiting toxicities,which occurred at dose level of 350 mg/m(2),were grade 4 neutropenia (1 out of 3 patients) and grade 3 diplopia (1 out of 3 patients). The MTD was thus determined at 300 mg/m(2). Among 21 patients who were evaluable for efficacy, 1 CR, 7 PR, 9 SD, 4 PD were observed, overall response rate (CR+PR) was 38%. CONCLUSION This phase I trial has demonstrated that Capxol has several advantages on clinical application, which include non-premedication required, shorter infusion time,higher paclitaxel MTD and safer toxicity. The results support for that a phase II clinical trial to further evaluate the antitumor activity of this drug in Chinese patients is worthy. The recommended dose for phase II clinical trial is 260 mg/m(2), I.V. over 30 minutes,and treatment repeats at every 3 weeks." @default.
- W2389274629 created "2016-06-24" @default.
- W2389274629 creator A5012401355 @default.
- W2389274629 creator A5023081058 @default.
- W2389274629 creator A5029588896 @default.
- W2389274629 creator A5074866331 @default.
- W2389274629 creator A5077937324 @default.
- W2389274629 creator A5079539570 @default.
- W2389274629 creator A5086694498 @default.
- W2389274629 creator A5087962211 @default.
- W2389274629 date "2004-11-01" @default.
- W2389274629 modified "2023-09-25" @default.
- W2389274629 title "[A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor]." @default.
- W2389274629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15566651" @default.
- W2389274629 hasPublicationYear "2004" @default.
- W2389274629 type Work @default.
- W2389274629 sameAs 2389274629 @default.
- W2389274629 citedByCount "0" @default.
- W2389274629 crossrefType "journal-article" @default.
- W2389274629 hasAuthorship W2389274629A5012401355 @default.
- W2389274629 hasAuthorship W2389274629A5023081058 @default.
- W2389274629 hasAuthorship W2389274629A5029588896 @default.
- W2389274629 hasAuthorship W2389274629A5074866331 @default.
- W2389274629 hasAuthorship W2389274629A5077937324 @default.
- W2389274629 hasAuthorship W2389274629A5079539570 @default.
- W2389274629 hasAuthorship W2389274629A5086694498 @default.
- W2389274629 hasAuthorship W2389274629A5087962211 @default.
- W2389274629 hasConcept C126322002 @default.
- W2389274629 hasConcept C197934379 @default.
- W2389274629 hasConcept C2776694085 @default.
- W2389274629 hasConcept C2777063308 @default.
- W2389274629 hasConcept C2777292972 @default.
- W2389274629 hasConcept C2778300832 @default.
- W2389274629 hasConcept C2778375690 @default.
- W2389274629 hasConcept C29730261 @default.
- W2389274629 hasConcept C42219234 @default.
- W2389274629 hasConcept C71924100 @default.
- W2389274629 hasConcept C90924648 @default.
- W2389274629 hasConcept C98274493 @default.
- W2389274629 hasConceptScore W2389274629C126322002 @default.
- W2389274629 hasConceptScore W2389274629C197934379 @default.
- W2389274629 hasConceptScore W2389274629C2776694085 @default.
- W2389274629 hasConceptScore W2389274629C2777063308 @default.
- W2389274629 hasConceptScore W2389274629C2777292972 @default.
- W2389274629 hasConceptScore W2389274629C2778300832 @default.
- W2389274629 hasConceptScore W2389274629C2778375690 @default.
- W2389274629 hasConceptScore W2389274629C29730261 @default.
- W2389274629 hasConceptScore W2389274629C42219234 @default.
- W2389274629 hasConceptScore W2389274629C71924100 @default.
- W2389274629 hasConceptScore W2389274629C90924648 @default.
- W2389274629 hasConceptScore W2389274629C98274493 @default.
- W2389274629 hasLocation W23892746291 @default.
- W2389274629 hasLocation W23892746292 @default.
- W2389274629 hasOpenAccess W2389274629 @default.
- W2389274629 hasPrimaryLocation W23892746291 @default.
- W2389274629 hasRelatedWork W1968370199 @default.
- W2389274629 hasRelatedWork W1990642049 @default.
- W2389274629 hasRelatedWork W2006455189 @default.
- W2389274629 hasRelatedWork W2017886436 @default.
- W2389274629 hasRelatedWork W2023956360 @default.
- W2389274629 hasRelatedWork W2061333709 @default.
- W2389274629 hasRelatedWork W2067551135 @default.
- W2389274629 hasRelatedWork W2080712868 @default.
- W2389274629 hasRelatedWork W2121856950 @default.
- W2389274629 hasRelatedWork W2124447659 @default.
- W2389274629 hasRelatedWork W2161576352 @default.
- W2389274629 hasRelatedWork W2164223699 @default.
- W2389274629 hasRelatedWork W2282241253 @default.
- W2389274629 hasRelatedWork W2287961714 @default.
- W2389274629 hasRelatedWork W2382255163 @default.
- W2389274629 hasRelatedWork W2393084387 @default.
- W2389274629 hasRelatedWork W2406956776 @default.
- W2389274629 hasRelatedWork W2598038721 @default.
- W2389274629 hasRelatedWork W3141947057 @default.
- W2389274629 hasRelatedWork W3148035859 @default.
- W2389274629 hasVolume "23" @default.
- W2389274629 isParatext "false" @default.
- W2389274629 isRetracted "false" @default.
- W2389274629 magId "2389274629" @default.
- W2389274629 workType "article" @default.